508-95-2

Basic information

• Product Name: 17α,21-Dihydroxypregn-4-ene-3,11,20-trione 21-phosphate
• Synonyms: 17α,21-Dihydroxypregn-4-ene-3,11,20-trione 21-phosphate;21-Cortisonephosphoric acid;Cortisone phosphate
• CAS NO: 508-95-2
• Molecular Formula: C21H29O8P
• Molecular Weight: 440.42
• Mol File: 508-95-2.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 17α,21-Dihydroxypregn-4-ene-3,11,20-trione 21-phosphate(CAS DataBase Reference)
• NIST Chemistry Reference: 17α,21-Dihydroxypregn-4-ene-3,11,20-trione 21-phosphate(508-95-2)
• EPA Substance Registry System: 17α,21-Dihydroxypregn-4-ene-3,11,20-trione 21-phosphate(508-95-2)

Safety Data

• Hazardous Substances Data: 508-95-2(Hazardous Substances Data)

Usage

Chemical structure

A steroid hormone with a specific arrangement of carbon, hydrogen, and oxygen atoms in its molecular structure.

Production

Produced in the adrenal glands.

Role in the body

Key role in the regulation of various physiological processes.

Involvement in hormone synthesis

Involved in the synthesis of other steroid hormones, such as cortisol and aldosterone.

Metabolic effects

Affects the metabolism of carbohydrates, fats, and proteins.

Anti-inflammatory properties

Has anti-inflammatory properties, which help in reducing inflammation in the body.

Immunosuppressive properties

Has immunosuppressive properties, which help in suppressing the immune system's response.

Stress response

Plays a critical role in the body's response to stress.

Inflammation response

Plays a critical role in the body's response to inflammation.

Phosphate form

The phosphate form of the compound allows it to be easily transported and utilized by the body for various functions.

Upstream product

• 988-16-9 21-acetoxy-3,3-ethanediyldioxy-17-hydroxy-pregn-5-ene-11,20-dione 
• 5758-62-3 3,3-ethanediyldioxy-17-hydroxy-21-methanesulfonyloxy-pregn-5-ene-11,20-dione 
• 5739-01-5 3,3-ethanediyldioxy-17-hydroxy-21-iodo-pregn-5-ene-11,20-dione 
• 5758-65-6 3,3-ethane-1,2-diyldioxy-17,21-dihydroxy-pregn-5-ene-11,20-dione 
• 53-06-5 Cortisone 
• 5758-64-5 3,3-ethanediyldioxy-21-(bis-benzyloxy-phosphoryloxy)-17-hydroxy-pregn-5-ene-11,20-dione 
• 5758-63-4 21-iodocortisone 

Downstream Products

• 93644-70-3 C₃₀H₄₁N₃O₁₅P₂ 

Relevant articles and documents

Nucleoside conjugates. 6. Synthesis and comparison of antitumor activity of 1-β-D-arabinofuranosylcytosine conjugates of corticosteroids and selected lipophilic alcohols

Five new P1-(steroid-21-yl)-P2-(1-β-D-arabinofuranosylcytosin-5'-yl)pyrophosphat es (ara-CDP-steroids), five 1-β-D-arabinofuranosylcytosine 5'-O-(alkyl)phosphates (ara-CMP-alkyl esters), and two P1-(alkyl)-P2-(1-β-D-arabinofuranosylcytosin-5'-yl)pyrophosphate (ara-CDP-alkyl esters) have been prepared and evaluated against L1210 lymphoid leukemia in culture and in mice (C3D2F1/J). These include ara-CDP-11-deoxycorticosterone, ara-CDP-cortisone, ara-CDP-corticosterone, ara-CDP-cortexolone, and ara-CDP-prednisone, ara-CMP hexadecyl ester, ara-CMP 1-cyclohexylmethyl ester, ara-CMP 1-adamantylmethyl ester, ara-CMP 2-(1-adamanthyl)ethyl ester, ara-CMP 2-chloroethyl ester, ara-CDP hexadecyl ester, and ara-CDP 1-cyclohexylmethyl ester. The in vitro antitumor results indicated that ara-CDP-steroids were as active as the previously reported ara-CMP-steroids and that ara-CMP and ara-CDP-alkyl esters were less growth inhibiting than ara-CDP-steroids and ara-C. However, the in vivo antitumor results indicated that ara-CDP-steroids were generally less effective than the previous monophosphate derivatives. Among them ara-CDP-corticosterone and the known ara-CDP-cortisol showed greater efficacy than ara-C with ILS value of 152% and 209%, respectively, at the optimal dose of 40 and 80 (mg/kg)/day for 9 days, while that of ara-C was 138% at the optimum dose of 9.2 (mg/kg)/day. Generally, ara-CMP alkyl esters, given ip to the L1210 leukemic mice, were found to be toxic and ineffective. However, ara-CDP hexadecyl ester showed marginal activity (ILS, 38%). These preliminary results support the thesis that the ara-C conjugates of this type may require a lipophilic and naturally occurring moiety for improved efficacy.